Predicting Immunotherapy Response in Metastatic Kidney Cancer


About this study

Immunotherapy has revolutionized the therapeutic landscape for patients with metastatic RCC and response rates are higher than previously observed with tyrosine kinase inhibitors. Despite this, there is a growing need for molecular markers that can help identify patients who will benefit from immunotherapy, especially in the landscape of multiple available regimens, potential toxicities and financial burden. In this study, we propose to use blood biopsies to study tumor-derived extracellular vesicles (tdEVs) to assess disease burden, monitor response to therapy, and to predict earlier disease progression. In addition to tdEVs, these samples will also be analyzed for other biomarkers (circulating immune cells) to assess if they can be used to inform on tumor-immune cell interactions in real-time and potentially identify responders to immunotherapy.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age 18+.
  • Able to give informed consent.
  • Newly diagnosed metastatic renal cell carcinoma.
  • Eligible for immunotherapy.

Exclusion Criteria:

  • Unable of unwilling to provide informed consent.
  • Previous systemic therapy.

Eligibility last updated 8/11/21. Questions regarding updates should be directed to the study team contact.



Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Fabrice Lucien-Matteoni, Ph.D.

Open for enrollment

Contact information:

Kathryn Barthels B.S.

(507) 538-5772

More information


Publications are currently not available

Mayo Clinic Footer